Medical Breakthroughs
Healthcare AI Valuation: A Comp Analysis for Investors
The pursuit of robust valuation benchmarks within the rapidly evolving healthcare AI landscape presents a critical…
Medical Breakthroughs
Medical Breakthroughs
FDA AI/ML Guidance: Investor Impact on Cardiac AI SaMD
The regulatory landscape for artificial intelligence and machine learning (AI/ML) in healthcare is in constant flux,…
Medical Breakthroughs
AI Health: $167M Fines Reshape Investment & Regulatory De-risking
The year 2026 has marked a critical inflection point for the burgeoning AI in healthcare sector,…
Medical Breakthroughs
FDA’s AI Crackdown: What Investors Need to Know Now
The landscape of healthcare AI investment is fundamentally shifting. No longer is innovation alone sufficient; regulatory…
Medical Breakthroughs
AMA’s AI Legislation: Your Cardiac AI Investment De-Risking Guide
The American Medical Association’s (AMA) recent push for formal AI oversight legislation in healthcare marks a…
Medical Breakthroughs
Healthcare AI ROI: Beyond Vendor Claims to Verified Value
The landscape of digital health is awash with bold claims of return on investment (ROI). Every…
Medical Breakthroughs
AI Health Regulation: Top 10 Investor Insights This Quarter
The intricate dance between innovation and regulation in healthcare AI is a constant source of both…
Chronic Conditions
Teladoc-Livongo: The $18.5 Billion Valuation Trap & AI Lessons
The healthcare AI landscape is rife with innovation, promising transformative shifts in patient care and operational…
Chronic Conditions
Teladoc’s Billion-Dollar Blunder: Validating Clinical-First AI
The healthcare AI landscape is littered with cautionary tales, but few resonate with the stark clarity…
Medical Breakthroughs
Bakul Patel: De-Risking AI Health for Investors
The article accurately reflects Bakul Patel’s past role and enduring influence on FDA digital health regulation.…